Roche Gains FDA Clearance for Respiratory Test Panel
Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel configurations, enabling labs and clinicians to rapidly and accurately identify the cause of respiratory infections to help ensure timely and effective patient care.
During peak respiratory seasons, health systems face immense pressure to accurately differentiate viral and bacterial infections that often have overlapping symptoms. When clinicians have accurate and rapid respiratory results, they can reduce the number of tests and radiographs ordered, decrease unnecessary antibiotic use and decrease the length of time to discharge.1
"Timely and accurate respiratory testing in critical situations can guide life-saving interventions. The cobas® eplex RP3 panel gives laboratories the range of testing choices they need with quick turnaround times that can make a difference in patient care." — Dan Malarek, President and CEO of Roche Diagnostics North America